Incidence of intracranial tumours in the Lothian region of Scotland, 1989–90

Carl E Counsell, Donald A Collie, Robert Grant

Abstract

Objective—To determine the incidence of primary and secondary intracranial tumours in the Lothian region of southeast Scotland.

Methods—A population based study was performed. Patients from Lothian with incident intracranial tumours diagnosed in 1989 and 1990 (by CT or histology) were identified retrospectively using multiple sources. Differences in incidence by tumour type, age, sex, and socioeconomic status were examined.

Results—Four hundred and forty two patients with incident intracranial tumours were identified (228 primary tumours and 214 secondary tumours). The crude yearly incidences of primary and secondary tumours were 15·3 and 14·3 per 100 000 respectively. The commonest primary tumours were neuroepithelial tumours (53·5%), meningeal tumours (19·5%), and sellar tumours (16·5%). About 50% of patients with secondary tumours had an underlying lung cancer. The incidence of primary and secondary tumours increased markedly with age. Meningeal tumours were more common in women, and neuroepithelial tumours were more common in those who lived in more affluent areas.

Conclusions—The incidence rates of primary and secondary intracranial tumours in Lothian were more than twice those previously reported in the United Kingdom. Intracranial tumours are a significant cause of morbidity and mortality in the United Kingdom, and further research into their aetiology and treatment is urgently required.

(J Neurol Neurosurg Psychiatry 1996;61:143–150)

Keywords: Intracranial tumours; incidence; epidemiology

Accurate data on the incidence of intracranial tumours are required by those who plan the provision of health services and by researchers in the field, as variations in incidence by age, sex, socioeconomic status, time, and place can provide important clues to aetiological factors. Changes in incidence over time are particularly important with respect to intracranial tumours as there have been several recent reports suggesting that the incidence and mortality rates from primary intracranial tumours have been increasing in several countries over the past 50 years, particularly in elderly people. Some authors have argued that the increase is artefactual due to: (a) the introduction of simpler, more accurate diagnostic techniques such as CT; (b) the increase in the number of neurologists in some countries; (c) the improved care of elderly people; (d) changes in coding classification; and (e) misclassification of secondary brain tumours as primary tumours. Others have argued that this cannot explain all of the apparent increase.

Accurate and reliable incidence studies are therefore required to: (a) allow adequate assessment of the true burden of intracranial tumours in society; (b) allow appropriate planning of cancer services for these patients in the future; (c) define whether the increase in incidence is real and continuing or not; and (d) enhance epidemiological research into possible risk factors for intracranial cancer. However, there have been few studies of the incidence of intracranial tumours and only three of these have been performed in the United Kingdom. Two predated the widespread use of CT; the other was restricted to patients seen in one neurosurgical department in south Wales. A population based incidence study was therefore performed in the Lothian region of Scotland to describe the overall incidence of both primary and secondary intracranial tumours. A report of the incidence of gliomas in the working population has been published elsewhere.

Subjects and methods

Figure 1 shows the study area. During the study period, the Lothian region was served by one neurology department (providing services at the Western General Hospital, the Royal Infirmary in Edinburgh, and St John’s Hospital in Livingston), one neurosurgery department, one neuropathology laboratory, one oncology and radiotherapy department (all based at the Western General Hospital), two endocrine departments, and two paediatric departments. Three hospitals in Lothian had CT machines, two of which had been available for over 10 years (at the Western General Hospital and the Royal Infirmary in Edinburgh) and one of which was installed early in 1990 (at St John’s Hospital, Livingston). One hospital (the Royal Infirmary) could perform MRI. Patients from Lothian with suspected intracranial tumours are unlikely to have been referred outside the
DEFINITIONS

Incident cases

All patients who were normally resident in the Lothian region (as defined by an EH postcode) and in whom the diagnosis of any new intracranial tumour was made between 1 January 1989 and 31 December 1990 were included, whether symptomatic or asymptomatic. Patients with recurrent intracranial tumours were excluded. The date of diagnosis was taken as either the date of the first abnormal CT or MRI (whichever was first), or the date of necropsy in those who did not have a scan. Patients with a purely clinical diagnosis of intracranial tumour in whom there was no neuroradiology or histology were excluded as were spinal tumours and primary tumours of the retina.

Intracranial tumours

The intracranial tumours were classified into eight categories (table 1) on the basis of the second World Health Organisation (WHO) classification. Tumours were classified, where possible, on the basis of histology, all of which was performed in the neuropathology department at the Western General Hospital. If no histology was available, then the tumours were classified on the basis of their appearance on CT or MRI, their clinical course, and, in the case of pituitary tumours, an appropriately investigated endocrine abnormality. In the absence of histology, single hemispheric lesions in patients with no history of systemic cancer were usually classified as either gliomas, meningiomas, or solitary metastases, and multiple lesions were usually presumed to be metastases. A previous study from the Western General Hospital showed that the CT diagnosis of a solitary glioma or meningioma was correct in 90% of cases but that CT diagnosis of a solitary metastasis was correct in only 50% of cases biopsied, the other 50% of cases being gliomas. In addition, a recent study of multifocal brain lesions in patients with no history of systemic cancer showed that 60% of such lesions were found to be neuroepithelial tumours on biopsy. A separate analysis was therefore planned in which 50% of those with a radiological diagnosis of solitary metastasis and no known primary cancer, and 60% of those with a radiological diagnosis of multiple metastases and no known primary cancer were reclassified as gliomas.

Socioeconomic status

The incidence of intracranial tumours may vary by social class. In this study, socioeconomic status was assigned to each patient on the basis of the Carstairs deprivation score for the postcode sector of their place of residence (see Appendix 1). Social class based on the patient’s occupation was not used because this was not always available from the hospital notes and was difficult to define accurately in patients who were retired or not working. For the purposes of this study, the Carstairs score was divided into seven deprivation categories as previously defined, category 1 being the most affluent and category 7 the most deprived.

---

**Table 1** Types of tumour identified and percentage with histological confirmation

<table>
<thead>
<tr>
<th>WHO tumour type</th>
<th>No of patients</th>
<th>No (%) with histology</th>
</tr>
</thead>
<tbody>
<tr>
<td>All primary tumours</td>
<td>228</td>
<td>158 (69)</td>
</tr>
<tr>
<td>Neuroepithelial tumours</td>
<td>122</td>
<td>88 (72)</td>
</tr>
<tr>
<td>Astrocytic</td>
<td>99</td>
<td></td>
</tr>
<tr>
<td>Oligodendrogial</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Mixed glioma</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Ependymalomal</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Pineal</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Embryonal</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Meningeal tumours</td>
<td>45</td>
<td>35 (78)</td>
</tr>
<tr>
<td>Meningioma</td>
<td>41</td>
<td></td>
</tr>
<tr>
<td>Haemangiblastoma</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Haemangiopericytoma</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Lipoma</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Sellar region</td>
<td>38</td>
<td>18 (47)</td>
</tr>
<tr>
<td>Pituitary</td>
<td>35</td>
<td></td>
</tr>
<tr>
<td>Craniohypophysealgioma</td>
<td>3</td>
<td>8 (80)</td>
</tr>
<tr>
<td>Cranial nerve tumours</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Acoustic schwannoma</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Primary CNS lymphomas</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Germ cell tumours</td>
<td>1</td>
<td>100</td>
</tr>
<tr>
<td>Cystic tumour-like lesions</td>
<td>2</td>
<td>2 (100)</td>
</tr>
<tr>
<td>All secondary tumours</td>
<td>214</td>
<td>24 (11)</td>
</tr>
<tr>
<td>Single</td>
<td>95</td>
<td>18 (19)</td>
</tr>
<tr>
<td>Multiple</td>
<td>119</td>
<td>6 (5)</td>
</tr>
</tbody>
</table>

---

**Figure 1** A map of the study area.
CASE ASCERTAINMENT
To minimise the number of cases that may have been missed, multiple overlapping methods were used to identify eligible patients. The following were reviewed: (1) the reports of all cranial CT performed at the three radiology departments with CT scanners between 1 January 1989 to 31 December 1990; (2) neurology and neurosurgery discharges from 1 January 1989 to 1 April 1991; (3) cases attending the neuro-oncology clinic at the Western General Hospital in the two study years; (4) databases of patients attending the two endocrinology departments in the study period to identify patients with pituitary tumours; (5) neuropathology reports on brain specimens from 1 January 1989 to 31 December 1993; (6) case records of patients who had received cranial radiotherapy between 1 December 1989 and 1 April 1991; (7) details of all patients resident in Lothian who were registered in the Scottish Cancer Registry between October 1988 and April 1991 with codes relevant to intracranial tumours (see Appendix 2); (8) details of all patients resident in Lothian who were admitted to hospitals in south east Scotland between October 1988 and April 1991 and who had one of the relevant codes in their hospital discharge data were requested from the Information and Statistics Division of the Common Services Agency for the Scottish Health Service. Some of these searches were extended beyond 31 December 1990 because there may have been a delay between the time of the first abnormal CT (the incident date used in this study) and the time of hospital admission, biopsy, or radiotherapy.

DATA EXTRACTION
The case notes, CT or MRI, and histology reports of any patient identified using the above searches were traced and carefully reviewed to ensure that the diagnosis of intracranial tumour was correct, and that the diagnosis was made during the study period (for example, that there was no evidence of an abnormality on CT taken before 1989). Relevant demographic, clinical, and histological data were extracted by medically qualified staff using a standard form. If notes could not be traced, as much information as possible was extracted from the CT or histology request forms and reports. Patients who died were identified by linking the patient data to the Scottish death register which was then searched up to 31 December 1993. The data were entered into a standard computerised database (D Base IV, Borland International Inc) and a series of quality checks were performed. Any duplicate cases were identified and excluded.

STATISTICAL ANALYSIS
The population of Lothian for the study period (total 748 703: 360 565 male, 388 138 female) was taken as the average of the midyear estimates for 1989 and 1990 which were based on the 1981 and 1991 censuses (K Dargie, Population Branch, General Register Office, Scotland, personal communication). The annual incidence rate was calculated as the average rate over the two study years. Crude incidence rates were calculated from the total number of cases and the total population of Lothian. In addition, when the numbers of cases were sufficient (arbitrarily defined as 10 or more cases), age and sex specific rates were calculated. Ninety five per cent confidence intervals (95% CIs) were calculated assuming a Poisson distribution. To establish whether incidence rates varied significantly between male and female patients, the relative risk of each tumour was calculated for each sex using the Mantel-Haenszel technique to stratify for age in four bands (0–24 years, 25–44 years, 45–64 years, 65 or more years). The effect of socioeconomic status on the incidence of all primary tumours, of neuroepithelial tumours (the largest subgroup of primary tumours), and of all secondary tumours was also examined by calculating the incidence for each separate Carstairs deprivation category. The $\chi^2$ test for trend was used to assess whether there was a significant linear relation between incidence and age and deprivation category.

Statistical analyses were performed using the Epi Info (version 5) and SPSS (version 4-0-1) statistical packages.

ETHICS
Ethical approval was obtained from the health boards in south east Scotland to access hospital discharge data and the Scottish Cancer Registry.

Results
During the two year period, a total of 442 patients with incident intracranial tumours were identified. One hundred and fifty two patients (124 primary, 28 secondary) were identified in the Cancer Registry. Fifty three patients (12%) were not, as far as we can tell, admitted to hospital. A further 30 patients were excluded: no notes, CT report, or histology report were available to confirm a suspicion of intracranial tumour in 23; the diagnosis was based on clinical grounds alone in five; and two patients were not resident in Lothian at the time of the diagnosis. Twenty two patients (5%) were included on the basis of CT or histology report alone as clinical notes could not be traced. In all except two patients, the initial diagnostic investigation had been CT: in one patient, asymptomatic multiple meningiomas were found at necropsy, and another patient, who was presumed to have had a stroke, was found to have a glioblastoma at necropsy. Only two patients out of the 420 patients whose notes were available had definitely asymptomatic tumours: the patient with multiple meningiomas described above and another in whom a meningioma was found on CT which had been performed for another indication.

Table 1 shows the numbers of patients with the different types of tumour and the percentage confirmed with histology. Histology was...
available for 182 (41%) patients overall (169 biopsies, 13 necropsies), and for 69% of primary tumours and 11% of secondary tumours. The overall necropsy rate was low: 326 patients died during follow up of at least three years, and only 18 had necropsies (6%). Two hundred and twenty eight cases of primary intracranial tumour were identified (52% of all tumours, 95% CI 47%-56%). Of these 53-5% were neuroepithelial tumours, 19-5% were meningeal tumours, 16-5% were sellar tumours, 4-5% were cranial nerve tumours, 4-5% were primary CNS lymphomas, 1% were cystic lesions, and 0-5% were germ cell tumours. Most (93%) of the neuroepithelial tumours were gliomas, of which 76% (86/114) were classified as high grade (glioblastoma, anaplastic astrocytoma, anaplastic oligodendroglioma). Of the 35 patients with pituitary tumours, 20 had non-functioning tumours, 12 had prolactinomas, and one each had a chromophobic tumour, a growth hormone secretory tumour, and an adenocarcinoma. Only one of the 10 patients with a primary CNS lymphoma was known to have AIDS. The single germ cell tumour was a pineal germinoma, and the two cystic lesions were a colloid cyst of the third ventricle and a dermoid cyst.

Secondary intracranial tumours were diagnosed in 214 patients (48% of all tumours, 95% CI 44%-53%). In four patients the secondary tumour was a direct extension from a local tumour, whereas in 210 the secondary tumour had metastatised from a distant primary tumour (lung cancer 112 cases (53%), unknown primary site 29 cases (14%), breast cancer 27 cases (13%), malignant melanoma 16 cases (8%), bowel cancer seven cases (3%), renal cancer four cases (2%), haematological cancers (two non-Hodgkin’s lymphomas, one acute myeloid leukaemia) three cases (1%), uterine cancer two cases (1%), and one each of adrenal cancer, bladder cancer, neuroblastoma of the eye, laryngeal cancer, oesophageal cancer, pancreatic cancer, prostatic cancer, rhabdomyosarcoma, sacral tumour of unknown type, and testicular teratoma). In 24 of the cases with an unknown primary tumour, there was no evidence of systemic cancer and the diagnosis of a secondary tumour was made on the basis of the CT appearance alone. Thirteen of these patients had multiple lesions and 11 had a single lesion on CT.

INCIDENCE

Table 2 gives the crude incidences for Lothian for each tumour type. If, in patients with no known primary cancer, 50% of solitary metastases and 60% of multiple metastases diagnosed radiologically were, in fact, gliomas, 13 patients in this study may have been misclassified as having secondary intracranial tumours. Reclassifying these as gliomas, the incidence of neuroepithelial tumours increased slightly to 9-1 per 100 000 per year (95% CI 7-6-10-7).

AGE RELATED DIFFERENCES IN INCIDENCE

Figure 2 shows the age distributions of patients with primary and secondary intracranial tumours. Patients with primary tumours were significantly younger than those with secondary tumours (mean age 53 (SD 20) years v 61 (SD 15) years; Student’s t test, P < 0-0001). The average ages of patients with different types of primary tumour were: neuroepithelial tumours 53 (SD 21), range 1–86 years; meningeal tumours 58 (SD 16), range 22–89 years; sellar tumours 46 (SD 18), range 17–84 years; cranial nerve tumours 55 (SD 14), range 39–86 years; primary CNS lymphoma 58 (SD 20), range 22–79 years. Table 3 gives age specific incidence rates of each tumour type. Analyses and interpretation of these data were limited by the few patients in many of the groups, especially in those aged under 14 and over 85 years, such that the 95% CIs were often very wide. The incidence of all primary tumours increased with age until a peak between the age of 65 and 74.
Table 3  Age specific incidence rates for each tumour type

<table>
<thead>
<tr>
<th>Age (s)</th>
<th>0-14</th>
<th>15-24</th>
<th>25-34</th>
<th>35-44</th>
<th>45-54</th>
<th>55-64</th>
<th>65-74</th>
<th>75-84</th>
<th>≥85</th>
</tr>
</thead>
<tbody>
<tr>
<td>All primary</td>
<td>3.5</td>
<td>6.1</td>
<td>6.2</td>
<td>10.4</td>
<td>10.4</td>
<td>10.4</td>
<td>13.7</td>
<td>18.3</td>
<td>29.7</td>
</tr>
<tr>
<td>Neuroepithelial</td>
<td>3.5</td>
<td>2.9</td>
<td>3.6</td>
<td>7.3</td>
<td>8.5</td>
<td>8.5</td>
<td>15.2</td>
<td>24.0</td>
<td>36.9</td>
</tr>
<tr>
<td>Meningeal</td>
<td>0.0</td>
<td>0.4</td>
<td>1.6</td>
<td>2.4</td>
<td>4.9</td>
<td>6.6</td>
<td>7.2</td>
<td>9.0</td>
<td>11.0</td>
</tr>
<tr>
<td>Sellar</td>
<td>0.0</td>
<td>1.6</td>
<td>4.4</td>
<td>2.9</td>
<td>1.2</td>
<td>1.2</td>
<td>5.9</td>
<td>2.4</td>
<td>3.8</td>
</tr>
<tr>
<td>Cranial nerve</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>1.0</td>
<td>3.1</td>
<td>0.6</td>
<td>0.8</td>
<td>0.0</td>
<td>1.0</td>
</tr>
<tr>
<td>CNS lymphoma</td>
<td>0.0</td>
<td>0.4</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>1.3</td>
<td>2.4</td>
<td>2.6</td>
<td>0.0</td>
</tr>
<tr>
<td>All secondary</td>
<td>1.5</td>
<td>0.4</td>
<td>2.0</td>
<td>7.8</td>
<td>19.5</td>
<td>39.5</td>
<td>53.7</td>
<td>36.0</td>
<td>4.8</td>
</tr>
</tbody>
</table>

Values are incidence/100,000/year (95% CI).

The same pattern was found if only neuroepithelial (χ² trend 53.6, P < 0.001) or meningeal tumours (χ² trend 37.8, P < 0.001) were considered, although for meningeal tumours the peak incidence was in those aged 75 to 84 years (table 3). There was the suggestion of a small second peak in incidence of neuroepithelial tumours in those aged under 14. There was no obvious relation between age and the incidence of sellar tumours (χ² trend 3.5, P = 0.06), and there were too few tumours in the other categories to identify any association between age and incidence.

The relation between age and the incidence of all secondary tumours seemed to be slightly different from that of primary tumours. There was an exponential increase in incidence until the age of 74 years. After this there was an apparent significant decrease in the incidence, particularly in those aged over 85 years (table 4).

SEX RELATED DIFFERENCES IN INCIDENCE

Table 4 shows the age and sex specific incidences of each tumour type, along with the age standardised relative risks of tumours in male as opposed to female subjects. Once
Table 4  Age and sex specific rates of patients with each tumour type

<table>
<thead>
<tr>
<th>Tumour type</th>
<th>Age (%)</th>
<th>No</th>
<th>Rate (95% CI)</th>
<th>No</th>
<th>Rate (95% CI)</th>
<th>No</th>
<th>Rate (95% CI)</th>
<th>No</th>
<th>Rate (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All primary</td>
<td>M</td>
<td>12</td>
<td>4.7 (2.4-8.1)</td>
<td>27</td>
<td>11.9 (7.9-17.3)</td>
<td>33</td>
<td>21.8 (15.0-30.6)</td>
<td>32</td>
<td>37.8 (25.9-53.3)</td>
</tr>
<tr>
<td></td>
<td>F</td>
<td>12</td>
<td>4.9 (2.5-8.5)</td>
<td>27</td>
<td>11.9 (7.9-17.3)</td>
<td>41</td>
<td>25.0 (17.9-33.9)</td>
<td>44</td>
<td>31.7 (23.1-42.6)</td>
</tr>
<tr>
<td>Neuroepithelial</td>
<td>M</td>
<td>8</td>
<td>3.1 (1.3-6.1)</td>
<td>13</td>
<td>5.7 (3.0-9.8)</td>
<td>17</td>
<td>11.2 (6.5-18.0)</td>
<td>23</td>
<td>27.2 (17.2-40.8)</td>
</tr>
<tr>
<td></td>
<td>F</td>
<td>8</td>
<td>3.2 (1.4-6.4)</td>
<td>11</td>
<td>4.9 (2.4-8.7)</td>
<td>19</td>
<td>11.6 (7.0-19.1)</td>
<td>23</td>
<td>16.6 (10.5-24.9)</td>
</tr>
<tr>
<td>Meningeal</td>
<td>M</td>
<td>0</td>
<td>0.0 (0.0-1.4)</td>
<td>4</td>
<td>1.9 (0.5-4.5)</td>
<td>4</td>
<td>2.6 (0.7-6.8)</td>
<td>4</td>
<td>4.7 (1.3-12.1)</td>
</tr>
<tr>
<td></td>
<td>F</td>
<td>1</td>
<td>0.4 (0.0-2.3)</td>
<td>5</td>
<td>2.2 (0.7-5.1)</td>
<td>14</td>
<td>8.5 (4.7-14.3)</td>
<td>13</td>
<td>9.4 (5.0-16.0)</td>
</tr>
<tr>
<td>Sellar</td>
<td>M</td>
<td>2</td>
<td>0.8 (0.1-2.8)</td>
<td>7</td>
<td>3.1 (1.2-6.3)</td>
<td>5</td>
<td>3.3 (1.1-7.7)</td>
<td>3</td>
<td>3.5 (0.7-10.4)</td>
</tr>
<tr>
<td></td>
<td>F</td>
<td>2</td>
<td>0.8 (0.1-2.9)</td>
<td>10</td>
<td>4.4 (2.1-8.1)</td>
<td>6</td>
<td>3.7 (1.3-8.0)</td>
<td>3</td>
<td>2.2 (0.4-6.3)</td>
</tr>
<tr>
<td>Cranial nerve†</td>
<td>M</td>
<td>0</td>
<td>0.0 (0.0-1.4)</td>
<td>1</td>
<td>0.4 (0.0-2.4)</td>
<td>5</td>
<td>3.3 (1.1-7.7)</td>
<td>0</td>
<td>0.0 (0.0-0.4)</td>
</tr>
<tr>
<td></td>
<td>F</td>
<td>0</td>
<td>0.0 (0.0-1.5)</td>
<td>1</td>
<td>0.4 (0.0-2.4)</td>
<td>1</td>
<td>0.6 (0.0-3.4)</td>
<td>2</td>
<td>1.4 (0.2-5.2)</td>
</tr>
<tr>
<td>CNS lymphoma†</td>
<td>M</td>
<td>1</td>
<td>0.4 (0.0-2.2)</td>
<td>1</td>
<td>0.4 (0.0-2.4)</td>
<td>2</td>
<td>1.3 (0.2-4.8)</td>
<td>2</td>
<td>2.4 (0.3-8.5)</td>
</tr>
<tr>
<td></td>
<td>F</td>
<td>0</td>
<td>0.0 (0.0-1.5)</td>
<td>0</td>
<td>0.0 (0.0-1.6)</td>
<td>1</td>
<td>0.6 (0.0-3.4)</td>
<td>3</td>
<td>2.2 (0.4-6.3)</td>
</tr>
<tr>
<td>Cyst†</td>
<td>M</td>
<td>1</td>
<td>0.0</td>
<td>0</td>
<td>0.0</td>
<td>0</td>
<td>0.0</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td></td>
<td>F</td>
<td>1</td>
<td>0.0</td>
<td>0</td>
<td>0.0</td>
<td>0</td>
<td>0.0</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td>Germ cell‡</td>
<td>M</td>
<td>0</td>
<td>0.0</td>
<td>1</td>
<td>0.0</td>
<td>0</td>
<td>0.0</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td></td>
<td>F</td>
<td>0</td>
<td>0.0</td>
<td>0</td>
<td>0.0</td>
<td>0</td>
<td>0.0</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td>All secondary</td>
<td>M</td>
<td>2</td>
<td>0.8 (0.1-2.8)</td>
<td>2</td>
<td>0.9 (0.1-3.2)</td>
<td>45</td>
<td>29.7 (21.7-39.8)</td>
<td>53</td>
<td>62.6 (46.9-81.9)</td>
</tr>
<tr>
<td></td>
<td>F</td>
<td>3</td>
<td>1.2 (0.3-3.6)</td>
<td>19</td>
<td>8.4 (5.0-13.1)</td>
<td>47</td>
<td>28.6 (21.0-38.1)</td>
<td>43</td>
<td>31.0 (22.4-41.8)</td>
</tr>
</tbody>
</table>

*Relative risk stratified for age using Mantel-Haenszel analysis. †Numbers too small to allow Mantel-Haenszel analysis for M:F relative risk. Unstratified relative risk calculated. ‡Age-sex specific rates not calculated because of very small numbers.

again, the numbers of tumours in most classes were small and, therefore, real differences may have been missed. There were no significant differences between the sexes in the incidence of all primary or secondary tumours, or in most of the subtypes of primary tumour. However, meningiial tumours were significantly more frequent in females than in males (2:2:1).

SOCIOECONOMIC STATUS AND INCIDENCE

Figure 3 shows the incidence of primary, neuroepithelial, and secondary tumours in each of the seven deprivation category areas. The apparent trend for the incidence of all primary intracranial tumours to be highest in the most affluent areas was not statistically significant ($\chi^2_{\text{trend}} = 0.16$, $P = 0.69$). However, there were significant linear relations between the incidence of neuroepithelial tumours and secondary tumours and deprivation category. The incidence of neuroepithelial tumours was 2-3 times higher in areas of greatest affluence (category 1 or 2) compared with the least affluent areas (category 6 or 7) ($\chi^2_{\text{trend}} = 4.56$, $P = 0.03$). For secondary intracranial tumours, the reverse relation was seen: the incidence was about twice as high in the least affluent areas compared with the most affluent areas ($\chi^2_{\text{trend}} = 6.18$, $P = 0.01$).

Discussion

The incidence of primary and secondary intracranial tumours in this study was two to three times greater than in previous studies in the United Kingdom, but less than was found in a recent study from northern Italy. The discrepancies between the results of the previous United Kingdom studies and the present study are likely to be mainly related to different methodologies (especially the methods used to identify cases), rather than true differences in incidence. We used extensive searches, including reviewing all CT, to identify all cases in a defined area of Scotland. In comparison, the previous studies were either restricted to patients admitted to a single hospital, or performed before CT was available.

Despite the extensive searches that were used to identify all incident cases of intracranial tumour in this study, it is very possible that some cases were missed. In particular, the study was not prospective, and so difficulties were encountered in tracing the notes and scans of some patients with possible tumours (23 patients were excluded on this basis). The decrease in incidence in very elderly people may be because cases were missed in this age group due to underinvestigation and diagnostic bias. General practitioner records were not used to identify patients and therefore some patients who were either not admitted to hospital or admitted to a hospital outside the study region may not have been identified (none of the patients identified from the Scottish Cancer Registry were admitted to hospitals outside the region, however). Death certificates were also not specifically screened during the study although they were monitored by the Scottish Cancer Registry. Very few asymptomatic patients were identified during the study. The few asymptomatic patients included was probably due to the low necropsy rate during the study period—less than 15% of patients who die in Scotland have a necropsy (General Register Office, personal communication). Previous studies have suggested that asymptomatic gliomas are found in about 0.5% of necropsies in those aged over 65 years, that asymptomatic meningiomas are found in about 1%–2% of all necropsies, and that secondary intracranial tumours are found in up to 40% of necropsies in patients with certain types of cancer. Also, necropsy reports were not routinely screened during the study period and not all necropsies that were performed included an examination of the CNS. This could have been improved if the
Incidence of intracranial tumours in the Lothian region of Scotland, 1989-90

Dennis, personal communication). One previous study from an area with a very high necropsy rate in the general population (which partly overcomes referral and diagnostic bias) showed that the incidence of meningeal tumours increased in all age groups but that the incidence of neuroepithelial tumours decreased in those aged over 85 years.\(^{10}\)

There were too few patients with each tumour type to reliably determine the relative incidences in male and female patients. Generally, however, there seemed to be little difference between the sexes except for meningeal tumours which were about twice as common in female as in male patients. The relation between the incidence of neuroepithelial tumours and socioeconomic status is interesting. For most other cancers the incidence has been shown to be higher in people with low socioeconomic status,\(^{19}\) which explains why, in this study, the incidence of secondary intracranial tumours increased with decreasing socioeconomic status. However, for neuroepithelial tumours the incidence decreased in people with lower socioeconomic status. This was unlikely to be a chance finding as a similar inverse relation was found in the Scottish Cancer Registry when over 3000 "brain and other CNS" tumours were analysed,\(^{16}\) and in neuroepithelial tumours in children.\(^{28}\)

The incidence rates for each socioeconomic group were not standardised for age, and therefore part of the explanation for the decrease in incidence may be that less affluent groups contained fewer elderly people, in whom the incidence is higher. However, this is unlikely to explain the twofold difference in incidence that was found. Referral bias may mean that patients from deprived areas are less likely to present to doctors or to be referred for investigation but most neuroepithelial tumours present with severe and progressive symptoms and signs which patients would find difficult to ignore. It is also unlikely that there was selective misclassification of neuroepithelial tumours—that is, that tumours in people from affluent areas were more often misdiagnosed as neuroepithelial. However, there could be misclassification of the socioeconomic status of the patient as this was based on the postcode of residence rather than on the actual socioeconomic status. Not all people living in a postcode sector with a particular deprivation category will have the same socioeconomic status. However, it might be expected that such misclassification would be most pronounced in areas with intermediate deprivation categories (categories 3, 4, and 5) rather than in areas of the greatest affluence. The association between high socioeconomic status and the increased incidence of neuroepithelial tumours could, therefore, be real.

In summary, the incidence of primary and secondary intracranial tumours in the United Kingdom is probably significantly higher than was previously thought. If the results of this study are confirmed, primary intracranial tumours would be the sixth most common tumour in both males and females in Scotland.\(^{18}\) The prognosis of most types of
primary intracranial tumour and of second tumours is very poor and has changed little over the past 10 years.29 There is, therefore, an urgent need for a coordinated approach among the many different specialties involved in the care of these patients (paediatrics, neurology, neurosurgery, oncology, and general medicine) to further research into the aetiology and treatment of intracranial tumours.

We thank all clinicians involved in the care of these patients and who helped to identify them, in particular Dr A Gregory (neurology), Mr I R Whittle (neurosurgery), and Dr J W Ironside (neuroendocrinology). We also thank Dr Peter Rothwell who helped extract data from case notes; Mr Stuart Griffen (audit assistant) who helped trace many of the case notes; and Mr Jim Slattery for statistical advice. This project was made possible by a grant from the Lothian Medical Audit Council. The research was supported by Wellcome Trust research training fellowship in clinical epidemiology.

Appendix 1: The Carstairs score
The Carstairs score is based on the following variables, which are obtained from census data:

1. overcrowding: the proportion of people living in households with a density of > 2 persons per room.
2. male unemployment: the proportion of economically active males seeking or waiting to start work.
3. low social class: the proportion of people in private households whose economically active head is in social class 4 or 5.
4. car ownership: the proportion of people in private households who do not own a car.

Appendix 2: International Classification of Diseases (version 9) codes relevant to intracranial tumours

191 Malignant neoplasms of brain
192 Malignant neoplasm of other and unspecified parts of nervous system
192-0 Cranial nerves
192-1 Cerebral meninges
192-8 Other
192-9 Part unspecified
194 Malignant neoplasm of other endocrine glands and related structures
194-3 Pituitary and craniopharyngeal duct
194-4 Pinal gland
198 Secondary neoplasm of other specified parts
198-3 Brain and spinal cord
198-4 Other parts of nervous system (meninges)
225 Benign neoplasm of brain and other parts of nervous system
225-0 Brain
225-1 Cranial nerves
225-2 Cerebral meninges
225-8 Other
225-9 Part unspecified
227 Benign neoplasm of other endocrine glands and related structures
227-3 Pituitary and craniopharyngeal duct
227-4 Pinal gland
237 Neoplasm of uncertain behaviour of endocrine glands and nervous system
237-0 Pituitary and craniopharyngeal duct
237-1 Pinal gland
237-5 Brain and spinal cord
237-6 Meninges
237-9 Cranial nerves
239 Neoplasm of unspecified nature
239-0 Brain
239-7 Other parts of nervous system (cranial nerves, meninges)
253 Disorders of pituitary gland and hypothalamic control

253-0 Acromegaly and gigantism
253-1 Other anterior pituitary hyperfunction